Biomarker discovery and molecular profiling are essential components of preclinical development, providing critical insights into disease mechanisms, treatment response, and patient stratification. By identifying molecular signatures and predictive biomarkers, researchers can refine therapeutic targets, monitor drug efficacy, and reduce translational gaps between animal models and human trials. These tools are especially important in oncology, neurology, and rare diseases, where heterogeneity and complexity demand precision-driven approaches. At MuriPhys, we are well equipped to support biomarker-focused studies through access to high-quality tissue collection and immunohistochemistry, along with partnerships for transcriptomic and proteomic profiling. Our integrated approach to in vivo experimentation and molecular analysis enables robust biomarker identification and validation within physiologically relevant models, accelerating the development of targeted, effective therapies.
Below is a list of available models commonly used by MuriPhys researchers:
- Genomic sequencing (Whole Exome/Whole Genome Sequencing) – Identifying tumor-specific mutations.
- RNA sequencing (RNA-seq, scRNA-seq) - Evaluating transcriptomic changes in response to treatment.
- Proteomics analysis - Understanding signaling pathways in tumors.
- Immunohistochemistry (IHC) and multiplex immunofluorescence - Assessing biomarker expression in tumor tissue.
Advanced Drug Administration & Serial Injections
We specialize in the following routes of administration:
Intravenous (IV), Intramuscular (IM), Subcutaneous (SC), Intrathecal (IT), Intra Peritoneal (IP), Oral Gavage (PO), Topical, Slow-infusion and Continuous Infusions – supporting accurate systemic or localized therapeutic exposure.
Serial Injections – Enabling longitudinal drug administration studies to monitor treatment effects over time.
Quality Control: Mycoplasma Testing
Cell-line quality control includes mycoplasma testing to identify contamination. The testing plan, cell identity checks and acceptance criteria are defined for the study and documented with the work.
At MuriPhys, we are dedicated to accelerating oncology drug discovery with specialized preclinical solutions. Contact us today to discuss how we can support your oncology research!
Discuss the tumor model, treatment strategy, readouts and study stage with our oncology team. We will work with you to define the methods, controls, deliverables, timing and budget.